دورية أكاديمية
أعرض في EDS

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.

التفاصيل البيبلوغرافية
العنوان: Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.
المؤلفون: Kjeldsen SAS; Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, 2400 Copenhagen, Denmark.; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Gluud LL; Gastro Unit, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Werge MP; Gastro Unit, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark., Pedersen JS; Gastro Unit, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark., Bendtsen F; Gastro Unit, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Alexiadou K; Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2BX, UK., Tan T; Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2BX, UK., Torekov SS; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Iepsen EW; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Jensen NJ; Department of Endocrinology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, 2400 Copenhagen, Denmark.; Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark., Richter MM; Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, 2400 Copenhagen, Denmark., Goetze JP; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Clinical Biochemistry, Rigshospitalet, 2100 Copenhagen, Denmark., Rungby J; Department of Endocrinology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, 2400 Copenhagen, Denmark.; Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark., Hartmann B; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Holst JJ; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark., Holst B; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Holt J; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Gustafsson F; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Cardiology, Rigshospitalet, 2100 Copenhagen, Denmark., Madsbad S; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital - Hvidovre, 2650 Hvidovre, Denmark., Svane MS; Gastro Unit, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.; Department of Endocrinology, Copenhagen University Hospital - Hvidovre, 2650 Hvidovre, Denmark., Bojsen-Møller KN; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.; Department of Endocrinology, Copenhagen University Hospital - Hvidovre, 2650 Hvidovre, Denmark., Wewer Albrechtsen NJ; Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, 2400 Copenhagen, Denmark.; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
المصدر: IScience [iScience] 2023 Oct 12; Vol. 26 (11), pp. 108190. Date of Electronic Publication: 2023 Oct 12 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2018]-
مستخلص: Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D, metabolic dysfunction-associated steatotic liver disease (MASLD), and following bariatric surgery, or GLP-1-receptor-agonist therapy. NEPa, but not neprilysin protein, was enhanced in obesity, T2D, and MASLD. Notably, MASLD associated with NEPa independently of BMI and HbA1c. NEPa decreased after bariatric surgery with a concurrent increase in OGTT-stimulated GLP-1. Diet-induced weight loss did not affect NEPa, but individuals randomized to 52-week weight maintenance with liraglutide (1.2 mg/day) decreased NEPa, consistent with another study following 6-week liraglutide (3 mg/day). A 90-min GLP-1 infusion did not alter NEPa. Thus, MASLD may drive exaggerated NEPa, and lowered NEPa following bariatric surgery or liraglutide therapy may contribute to the reported improved cardiometabolic effects.
Competing Interests: The authors declare no competing interests.
(© 2023 The Authors.)
References: Diabetes Obes Metab. 2020 Oct;22(10):1837-1846. (PMID: 32495988)
J Am Heart Assoc. 2017 Aug 18;6(8):. (PMID: 28862951)
Diabetes Care. 2010 Feb;33(2):375-7. (PMID: 19918005)
J Endocrinol. 2019 Nov;243(2):149-160. (PMID: 31454790)
Obes Surg. 2021 Jun;31(6):2545-2550. (PMID: 33538983)
J Am Heart Assoc. 2019 Aug 6;8(15):e012943. (PMID: 31345101)
Eur J Heart Fail. 2019 May;21(5):598-605. (PMID: 30520545)
Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. (PMID: 28330649)
J Am Coll Cardiol. 2015 Feb 24;65(7):657-65. (PMID: 25677426)
Clin Chem. 1992 Sep;38(9):1785-91. (PMID: 1526015)
Cardiovasc Diabetol. 2022 Jun 18;21(1):110. (PMID: 35717169)
Drug Metab Dispos. 2010 Nov;38(11):1944-53. (PMID: 20709939)
Surg Obes Relat Dis. 2021 Jul;17(7):1383-1391. (PMID: 33771461)
Diabetologia. 2019 Jul;62(7):1113-1122. (PMID: 31089754)
Islets. 2018;10(5):175-180. (PMID: 30142012)
Mech Ageing Dev. 2020 Dec;192:111363. (PMID: 32987038)
J Obes. 2013;2013:839275. (PMID: 23431426)
Diabetes. 2014 May;63(5):1725-37. (PMID: 24241533)
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3868-3876. (PMID: 31074791)
Regul Pept. 1995 Aug 22;58(3):149-56. (PMID: 8577927)
Am J Neurodegener Dis. 2012;1(3):266-79. (PMID: 23383397)
J Endocr Soc. 2021 May 16;5(9):bvab084. (PMID: 34337276)
Diabetes Obes Metab. 2014 Jan;16(1):9-21. (PMID: 23617798)
Neurosci Lett. 2004 Aug 26;367(1):85-7. (PMID: 15308303)
Endocrinology. 2017 Dec 1;158(12):4139-4151. (PMID: 29040429)
Int J Obes (Lond). 2015 May;39(5):834-41. (PMID: 25287751)
Circ Res. 2016 May 27;118(11):1844-55. (PMID: 27230645)
Diabetes Obes Metab. 2022 Oct;24(10):2017-2026. (PMID: 35676803)
J Intern Med. 2013 Mar;273(3):219-34. (PMID: 23163728)
JACC Heart Fail. 2015 Aug;3(8):629-36. (PMID: 26251090)
ESC Heart Fail. 2021 Apr;8(2):938-942. (PMID: 33638612)
J Histochem Cytochem. 2018 Jul;66(7):523-530. (PMID: 29553871)
Clin Endocrinol (Oxf). 2021 Feb;94(2):193-203. (PMID: 33064869)
BMJ Open Diabetes Res Care. 2020 Mar;8(1):. (PMID: 32209584)
Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E431-8. (PMID: 15126240)
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F263-F274. (PMID: 29561187)
Obes Surg. 2017 Oct;27(10):2724-2732. (PMID: 28801703)
J Clin Endocrinol Metab. 2013 Nov;98(11):4391-9. (PMID: 24057293)
EBioMedicine. 2016 May;7:112-20. (PMID: 27322465)
Biochem J. 1974 Mar;137(3):477-88. (PMID: 4423492)
N Engl J Med. 2014 Sep 11;371(11):993-1004. (PMID: 25176015)
Diabetes Obes Metab. 2018 Aug;20(8):2029-2033. (PMID: 29652095)
Hepatol Commun. 2020 Sep 01;4(11):1610-1623. (PMID: 33163832)
Int J Obes (Lond). 2011 Aug;35(8):1031-40. (PMID: 21042321)
Eur J Heart Fail. 2013 Sep;15(9):1062-73. (PMID: 23563576)
Diabetes. 2023 Mar 1;72(3):336-347. (PMID: 36478039)
Endocr Rev. 2014 Dec;35(6):992-1019. (PMID: 25216328)
فهرسة مساهمة: Keywords: Diabetology; Health sciences; Obesity medicine
تواريخ الأحداث: Date Created: 20231113 Latest Revision: 20231122
رمز التحديث: 20231123
مُعرف محوري في PubMed: PMC10638073
DOI: 10.1016/j.isci.2023.108190
PMID: 37953952
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-0042
DOI:10.1016/j.isci.2023.108190